New therapeutics to treat castrate-resistant prostate cancer

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Acar, Ömer ^a   Esen, Tarik ^a,b   Lack, Nathan A ^a  

^a AMERICAN HOSPITAL   (Turkey)

^b KOÇ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXYPREGNENOLONE; ABIRATERONE; ABIRATERONE ACETATE; CABAZITAXEL; CABOZANTINIB; CUSTIRSEN; CYTOCHROME P450 17; DENOSUMAB; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ENZALUTAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PREGNENOLONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SIPULEUCEL T; TESTOSTERONE; VINBLASTINE; VINCRISTINE; ZOLEDRONIC ACID; ANTIANDROGEN; ANTINEOPLASTIC AGENT;

ADRENAL INSUFFICIENCY; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HOT FLUSH; HUMAN; HYDROXYLATION; HYPERTENSION; HYPOKALEMIA; LEUKAPHERESIS; LIVER TOXICITY; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL PAIN; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; TREATMENT RESPONSE; VOMITING; CASTRATION; IMMUNOTHERAPY; MALE; METHODOLOGY; ORCHIECTOMY; PROSTATE TUMOR; RADIOTHERAPY; TREATMENT FAILURE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CASTRATION; HUMANS; IMMUNOTHERAPY; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; TREATMENT FAILURE;

EID: 84879309107     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/379641     Document Type: Review

References (57)

1. Huggins C., Hodges C. V., Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Ca-A Cancer Journal for Clinicians 1972 22 4 232 240 2-s2.0-0015370976
2. Tannock I. F., De Wit R., Berry W. R., Horti J., Pluzanska A., Chi K. N., Oudard S., Théodore C., James N. D., Turesson I., Rosenthal M. A., Eisenberger M. A., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine 2004 351 15 1502 1512 2-s2.0-4744366279 10.1056/NEJMoa040720
3. Scher H. I., Jia X., Chi K., De Wit R., Berry W. R., Albers P., Henick B., Waterhouse D., Ruether D. J., Rosen P. J., Meluch A. A., Nordquist L. T., Venner P. M., Heidenreich A., Chu L., Heller G., Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. Journal of Clinical Oncology 2011 29 16 2191 2198 2-s2.0-79957953692 10.1200/JCO.2010.32. 8815
4. Miles D. W., Chan A., Dirix L. Y., Cortés J., Pivot X., Tomczak P., Delozier T., Sohn J. H., Provencher L., Puglisi F., Harbeck N., Steger G. G., Schneeweiss A., Wardley A. M., Chlistalla A., Romieu G., Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology 2010 28 20 3239 3247 2-s2.0-77954700380 10.1200/JCO.2008.21.6457
5. Quinn D. I., Tangen C. M., Hussain M., Lara P., Goldkorn A., Garzotto M., Mack P. C., Carducci M. A., Monk J. P., Przemyslaw T., Van Veldhuizen P. J., Agarwal N., Higano C. S., Vogelzang N. J., Thompson I. M., SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC). Journal of Clinical Oncology 2012 30 supplement, abstract 4511
6. De Bono J. S., Oudard S., Ozguroglu M., Hansen S., MacHiels J. P., Kocak I., Gravis G., Bodrogi I., MacKenzie M. J., Shen L., Roessner M., Gupta S., Sartor A. O., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet 2010 376 9747 1147 1154 2-s2.0-77957682309 10.1016/S0140-6736(10)61389-X
7. de Bono J. S., Logothetis C. J., Molina A., Fizazi K., North S., Chu L., Chi K. N., Jones R. J., Goodman O. B., Saad F., Staffurth J. N., Mainwaring P., Harland S., Flaig T. W., Hutson T. E., Cheng T., Patterson H., Hainsworth J. D., Ryan C. J., Sternberg C. N., Ellard S. L., Flechon A., Saleh M., Scholz M., Efstathiou E., Zivi A., Bianchini D., Loriot Y., Chieffo N., Kheoh T., Haqq C. M., Scher H. I., Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 2011 364 1995 2005
8. Scher H. I., Fizazi K., Saad F., Taplin M. E., Sternberg C. N., Miller K., de Wit R., Mulders P., Chi K. N., Shore N. D., Armstrong A. J., Flaig T. W., Flechon A., Mainwaring P., Fleming M., Hainsworth J. D., Hirmand M., Selby B., Seely L., de Bono J. S., Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 2012 367 1187 1197
9. Kantoff P. W., Higano C. S., Shore N. D., Berger E. R., Small E. J., Penson D. F., Redfern C. H., Ferrari A. C., Dreicer R., Sims R. B., Xu Y., Frohlich M. W., Schellhammer P. F., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine 2010 363 5 411 422 2-s2.0-77955066199 10.1056/NEJMoa1001294
10. Sartor A. O., Heinrich D., O'Sullivan J. M., Fossa S. D., Chodaki A., Wiechno P. J., Logue J. P., Seke M., Widmark A., Johannessen D. C., Nilsson S., Hoskin P., Bottomley D., Coleman R. E., Vogelzang N. J., O'Bryan-Tear G., Garcia-Vargas J. E., Shan M., Parker C., Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: interim results of a phase III trial (ALSYMPCA). Journal of Clinical Oncology 2012 30 supplement, abstract 4551
11. Galletti E., Magnani M., Renzulli M. L., Botta M., Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem 2007 2 7 920 942 2-s2.0-41949119102 10.1002/cmdc.200600308
12. Bissery M. C., Bouchard H., Riou J. F., Vrignaud C., Combeau J., Bourzat J. D., Commercon A., Lavelle F., Preclinical evaluation of TXD258, a new taxoid. Proceedings of the 91st American Association for Cancer Research 2000 San Francisco, Calif, USA
13. Gelmon K. A., Latreille J., Tolcher A., Génier L., Fisher B., Forand D., D'Aloisio S., Vernillet L., Daigneault L., Lebecq A., Besenval M., Eisenhauer E., Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. Journal of Clinical Oncology 2000 18 24 4098 4108 2-s2.0-0034671296
14. Mita A. C., Denis L. J., Rowinsky E. K., De Bono J. S., Goetz A. D., Ochoa L., Forouzesh B., Beeram M., Patnaik A., Molpus K., Semiond D., Besenval M., Tolcher A. W., Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clinical Cancer Research 2009 15 2 723 730 2-s2.0-59449102526 10.1158/1078-0432.CCR-08-0596
15. Paller C. J., Antonarakis E. S., Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design, Development and Therapy 2011 5 117 124 2-s2.0-79952978362 10.2147/DDDT.S13029
16. Diéras V., Limentani S., Romieu G., Tubiana-Hulin M., Lortholary A., Kaufman P., Girre V., Besenval M., Valero V., Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Annals of Oncology 2008 19 7 1255 1260 2-s2.0-46249085475 10.1093/annonc/mdn060
17. Tilley W. D., Lim-Tio S. S., Horsfall D. J., Aspinall J. O., Marshall V. R., Skinner J. M., Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Research 1994 54 15 4096 4102 2-s2.0-0028111565
18. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., Kallioniemi O. P., In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 1995 9 4 401 406 2-s2.0-0028944138
19. Tran C., Ouk S., Clegg N. J., Chen Y., Watson P. A., Arora V., Wongvipat J., Smith-Jones P. M., Yoo D., Kwon A., Wasielewska T., Welsbie D., Chen C. D., Higano C. S., Beer T. M., Hung D. T., Scher H. I., Jung M. E., Sawyers C. L., Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009 324 5928 787 790 2-s2.0-65649090203 10.1126/science.1168175
20. Cheng H., Snoek R., Ghaidi F., Cox M. E., Rennie P. S., Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Research 2006 66 21 10613 10620 2-s2.0-33751270698 10.1158/0008-5472.CAN-06-0028
21. Chen C. D., Welsbie D. S., Tran C., Baek S. H., Chen R., Vessella R., Rosenfeld M. G., Sawyers C. L., Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 2004 10 1 33 39 2-s2.0-1842612441 10.1038/nm972
22. Culig Z., Comuzzi B., Steiner H., Bartsch G., Hobisch A., Expression and function of androgen receptor coactivators in prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 2004 92 4 265 271 2-s2.0-12344338583 10.1016/j.jsbmb.2004.10.003
23. Giri D., Ozen M., Ittmann M., Interleukin-6 is an autocrine growth factor in human prostate cancer. American Journal of Pathology 2001 159 6 2159 2165 2-s2.0-0035180451
24. Locke J. A., Guns E. S., Lubik A. A., Adomat H. H., Hendy S. C., Wood C. A., Ettinger S. L., Gleave M. E., Nelson C. C., Androgen Levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research 2008 68 15 6407 6415 2-s2.0-51049098138 10.1158/0008-5472.CAN-07-5997
25. Scher H. I., Anand A., Rathkopf D., Shelkey J., Morris M. J., Danila D. C., Larson S., Humm J., Fleisher M., Sawyers C. L., Beer T. M., Alumkal J., Sawyers C. L., Higano C. S., Yu E. Y., Taplin M. E., Efstathiou E., Hung D., Hirmand M., Seely L., Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. The Lancet 2010 375 9724 1437 1446 2-s2.0-77952105685 10.1016/S0140-6736(10)60172-9
26. Scher H. I., Fizazi K., Saad F., Taplin M. E., Sternberg C. N., Miller K., de Wit R., Mulders P., Hirmand M., Selby B., de Bono J. S., Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. Journal of Clinical Oncology 2012 30 supplement 5, abstract LBA1
27. Foster W. R., Car B. D., Shi H., Levesque P. C., Obermeier M. T., Gan J., Arezzo J. C., Powlin S. S., Dinchuk J. E., Balog A., Salvati M. E., Attar R. M., Gottardis M. M., Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011 71 5 480 488 2-s2.0-79951518634 10.1002/pros.21263
28. Clegg N. J., Wongvipat J., Joseph J. D., Tran C., Ouk S., Dilhas A., Chen Y., Grillot K., Bischoff E. D., Cai L., Aparicio A., Dorow S., Arora V., Shao G., Qian J., Zhao H., Yang G., Cao C., Sensintaffar J., Wasielewska T., Herbert M. R., Bonnefous C., Darimont B., Scher H. I., Smith-Jones P., Klang M., Smith N. D., De Stanchina E., Wu N., Ouerfelli O., Rix P. J., Heyman R. A., Jung M. E., Sawyers C. L., Hager J. H., ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research 2012 72 1494 1503
29. Auchus R. J., The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinology and Metabolism Clinics of North America 2001 30 1 101 119 2-s2.0-0035032081
30. Potter G. A., Elaine Barrie S., Jarman M., Rowlands M. G., Novel steroidal inhibitors of human cytochrome P45017 α (17 α -hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. Journal of Medicinal Chemistry 1995 38 13 2463 2471 2-s2.0-0029058770
31. Barrie S. E., Potter G. A., Goddard P. M., Haynes B. P., Dowsett M., Jarman M., Pharmacology of novel steroidal inhibitors of cytochrome p450(17 α) (17 α -hydroxylase/C17-20 lyase). Journal of Steroid Biochemistry and Molecular Biology 1994 50 5-6 267 273 2-s2.0-0028031372 10.1016/0960-0760(94)90131-7
32. Chan F. C. Y., Potter G. A., Barrie S. E., Haynes B. P., Rowlands M. G., Houghton J., Jarman M., 3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 α) (17 α -hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. Journal of Medicinal Chemistry 1996 39 17 3319 3323 2-s2.0-0029763048 10.1021/jm950749y
33. Ryan C. J., Smith M. R., Fong L., Rosenberg J. E., Kantoff P., Raynaud F., Martins V., Lee G., Kheoh T., Kim J., Molina A., Small E. J., Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. Journal of Clinical Oncology 2010 28 9 1481 1488 2-s2.0-77951523950 10.1200/JCO.2009.24.1281
34. Tolcher A. W., Chi K. N., Shore N. D., Pili R., Molina A., Acharya M., Kheoh T., Jiao J. J., Gonzalez M., Trinh A., Pankras C., Tran N., Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 2012 70 305 313
35. Fizazi K., Carducci M., Smith M., Damião R., Brown J., Karsh L., Milecki P., Shore N., Rader M., Wang H., Jiang Q., Tadros S., Dansey R., Goessl C., Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. The Lancet 2011 377 9768 813 822 2-s2.0-79952360832 10.1016/S0140-6736(10)62344-6
36. Jarman M., Elaine Barrie S., Liera J. M., The 16,17-double bond is needed for irreversible inhibition of human cytochrome P45017 α by abiraterone (17-(3-Pyridyl)androsta-5,16-dien-3 β -ol) and related steroidal inhibitors. Journal of Medicinal Chemistry 1998 41 27 5375 5381 2-s2.0-0032585605
37. Hara T., Kouno J., Kaku T., Takeuchi T., Kusaka M., Tasaka A., Yamaoka M., Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. Journal of Steroid Biochemistry and Molecular Biology 2013 134 80 91
38. Agus D. B., Stadler W., Shevrin D. H., Hart L., MacVicar G. R., Hamid O., Hainsworth J. D., Gross M. E., Wang J., de Leon L., MacLean D., Dreicer R., Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study. Journal of Clinical Oncology 2011 29 supplement, abstract 4531
39. Patel P. H., Kockler D. R., Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Annals of Pharmacotherapy 2008 42 1 91 98 2-s2.0-38049048619 10.1345/aph.1K429
40. Small E. J., Fratesi P., Reese D. M., Strang G., Laus R., Peshwa M. V., Valone F. H., Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. Journal of Clinical Oncology 2000 18 23 3894 3903 2-s2.0-0034554863
41. Higano C. S., Schellhammer P. F., Small E. J., Burch P. A., Nemunaitis J., Yuh L., Provost N., Frohlich M. W., Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009 115 16 3670 3679 2-s2.0-68549135290 10.1002/cncr.24429
42. Nabhan C., Gomella L. G., DeVries T., Whitmore J. B., Frohlich M. W., George D. J., An analysis to quantify the overall survival (OS) benefit of sipuleucel-T accounting for the crossover in the control arm of the IMPACT study. Journal of Clinical Oncology 2012 30 supplement 5, abstract 144
43. Huber M. L., Haynes L., Parker C., Iversen P., Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. Journal of the National Cancer Institute 2012 104 273 279
44. Henriksen G., Breistøl K., Bruland O. S., Fodstad O., Larsen R. H., Significant antitumor effect from bone-seeking, α -particle-emitting 223Ra demonstrated in an experimental skeletal metastases model. Cancer Research 2002 62 11 3120 3125 2-s2.0-0036606104
45. Henriksen G., Fisher D. R., Roeske J. C., Bruland O. S., Larsen R. H., Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. Journal of Nuclear Medicine 2003 44 2 252 259 2-s2.0-0037315930
46. Nilsson S., Franzen L., Parker C., Tyrrell C., Blom R., Tennvall J., Lennernas B., Petersson U., Johannessen D. C., Sokal M., Pigott K., Yachnin J., Garkavij M., Strang P., Harmenberg J., Bolstad B., Bruland O. S., Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. The Lancet Oncology 2007 8 587 594
47. Logothetis C. J., Lin S. H., Osteoblasts in prostate cancer metastasis to bone. Nature Reviews Cancer 2005 5 1 21 28 2-s2.0-11144237716 10.1038/nrc1528
48. Smith M. R., Saad F., Coleman R., Shore N., Fizazi K., Tombal B., Miller K., Sieber P., Karsh L., Damiao R., Tammela T. L., Egerdie B., Van Poppel H., Chin J., Morote J., Gomez-Veiga F., Borkowski T., Ye Z., Kupic A., Dansey R., Goessl C., Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. The Lancet 2012 379 39 46
49. Sowery R. D., Hadaschik B. A., So A. I., Zoubeidi A., Fazli L., Hurtado-Coll A., Gleave M. E., Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. British Journal of Urology International 2008 102 3 389 397 2-s2.0-47649133156 10.1111/j.1464-410X.2008.07618.x
50. Miyake H., Chi K. N., Gleave M. E., Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clinical Cancer Research 2000 6 5 1655 1663 2-s2.0-0034112089
51. Zellweger T., Miyake H., Cooper S., Chi K., Conklin B. S., Monia B. P., Gleave M. E., Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy) ethyl chemistry. Journal of Pharmacology and Experimental Therapeutics 2001 298 3 934 940 2-s2.0-0034883854
52. Chi K. N., Eisenhauer E., Fazli L., Jones E. C., Goldenberg S. L., Powers J., Tu D., Gleave M. E., A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. Journal of the National Cancer Institute 2005 97 17 1287 1296 2-s2.0-24744470522 10.1093/jnci/dji252
53. Chi K. N., Hotte S. J., Yu E. Y., Tu D., Eigl B. J., Tannock I., Saad F., North S., Powers J., Gleave M. E., Eisenhauer E. A., Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology 2010 28 27 4247 4254 2-s2.0-77957957234 10.1200/JCO.2009.26.8771
54. Saad F., Hotte S., North S., Eigl B., Chi K., Czaykowski P., Wood L., Pollak M., Berry S., Lattouf J. B., Mukherjee S. D., Gleave M., Winquist E., Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clinical Cancer Research 2011 17 5765 5773
55. Release F. P., FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder. 2013, http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm337195.htm
56. Yakes F. M., Chen J., Tan J., Yamaguchi K., Shi Y., Yu P., Qian F., Chu F., Bentzien F., Cancilla B., Orf J., You A., Laird A. D., Engst S., Lee L., Lesch J., Chou Y. C., Joly A. H., Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Molecular Cancer Therapeutics 2011 10 2298 2308
57. Smith D. C., Smith M. R., Sweeney C., Elfiky A. A., Logothetis C., Corn P. G., Vogelzang N. J., Small E. J., Harzstark A. L., Gordon M. S., Vaishampayan U. N., Haas N. B., Spira A. I., Lara P. N., Lin C. C., Srinivas S., Sella A., Schoffski P., Scheffold C., Weitzman A. L., Hussain M., Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of Clinical Oncology 2013 31 412 419